A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

被引:8
|
作者
Fleseriu, M. [1 ]
Zhang, Z. [2 ]
Hanman, K. [3 ]
Haria, K. [3 ]
Houchard, A. [4 ]
Khawaja, S. [5 ]
Ribeiro-Oliveira, A., Jr. [6 ]
Gadelha, M. [7 ]
机构
[1] Oregon Hlth & Sci Univ, Pituitary Ctr, Portland, OR 97239 USA
[2] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Endocrinol & Metab, Shanghai, Peoples R China
[3] Costello Med, London, England
[4] Ipsen Pharma, Boulogne Billancourt, France
[5] World Alliance Pituitary Org, Zeeland, Netherlands
[6] Ipsen, Cambridge, MA USA
[7] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil
关键词
Acromegaly; Extended dosing intervals; Growth hormone; Somatostatin receptor ligand; Pituitary adenoma; ACTING SOMATOSTATIN ANALOGS; LANREOTIDE-AUTOGEL; OCTREOTIDE LAR; WEEKLY PEGVISOMANT; REAL-WORLD; 120; MG; EFFICACY; COMBINATION; SAFETY; CABERGOLINE;
D O I
10.1007/s11102-022-01285-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose This systematic literature review investigated whether extended dosing intervals (EDIs) of pharmacological acromegaly treatments reduce patient burden and costs compared with standard dosing, while maintaining effectiveness. Methods MEDLINE/Embase/the Cochrane Library (2001-June 2021) and key congresses (2018-2021) were searched and identified systematic literature review bibliographies reviewed. Included publications reported on efficacy/effectiveness, safety and tolerability, health-related quality of life (HRQoL), and patient-reported and economic outcomes in longitudinal/cross-sectional studies in adults with acromegaly. Interventions included EDIs of pegvisomant, cabergoline, and somatostatin receptor ligands (SRLs): lanreotide autogel/depot (LAN), octreotide long-acting release (OCT), pasireotide long-acting release (PAS), and oral octreotide; no comparator was required. Results In total, 35 publications reported on 27 studies: 3 pegvisomant monotherapy, 11 pegvisomant combination therapy with SRLs, 9 LAN, and 4 OCT; no studies reported on cabergoline, PAS, or oral octreotide at EDIs. Maintenance of normal insulin-like growth factor I (IGF-I) was observed in >= 70% of patients with LAN (1 study), OCT (1 study), and pegvisomant monotherapy (1 study). Achievement of normal IGF-I was observed in >= 70% of patients with LAN (3 studies) and pegvisomant in combination with SRLs (4 studies). Safety profiles were similar across EDI and standard regimens. Patients preferred and were satisfied with EDIs. HRQoL was maintained and cost savings were provided with EDIs versus standard regimens. Conclusions Clinical efficacy/effectiveness, safety, and HRQoL outcomes in adults with acromegaly were similar and costs lower with EDIs versus standard regimens. Physicians may consider acromegaly treatment at EDIs, especially for patients with good disease control.
引用
收藏
页码:9 / 41
页数:33
相关论文
共 50 条
  • [1] A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
    M. Fleseriu
    Z. Zhang
    K. Hanman
    K. Haria
    A. Houchard
    S. Khawaja
    A. Ribeiro-Oliveira
    M. Gadelha
    Pituitary, 2023, 26 : 9 - 41
  • [2] Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
    Bernabeu, Ignacio
    Fajardo, Carmen
    Marazuela, Monica
    Cordido, Fernando
    Maria Venegas, Eva
    de Pablos-Velasco, Pedro
    Piedrola Maroto, Gonzalo
    Pilar Olvera, Maria
    Pavon de Paz, Isabel
    Carvalho, Davide
    Romero, Carme
    De la Cruz, Guillermo
    Alvarez Escola, Cristina
    ENDOCRINE, 2020, 70 (03) : 575 - 583
  • [3] Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
    Ignacio Bernabéu
    Carmen Fajardo
    Mónica Marazuela
    Fernando Cordido
    Eva María Venegas
    Pedro de Pablos-Velasco
    Gonzalo Piedrola Maroto
    María Pilar Olvera
    Isabel Pavón de Paz
    Davide Carvalho
    Carme Romero
    Guillermo De la Cruz
    Cristina Álvarez Escolá
    Endocrine, 2020, 70 : 575 - 583
  • [4] Pharmacological Management of Bronchorrhea in Malignant Disease: A Systematic Literature Review
    Remi, Constanze
    Remi, Jan
    Bausewein, Claudia
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (05) : 916 - 925
  • [5] Laryngeal manifestations in acromegaly: a systematic review of the literature
    Smaily, Hussein
    Matar, Nayla
    ACTA OTO-LARYNGOLOGICA CASE REPORTS, 2020, 5 (01): : 57 - 63
  • [6] Pharmacological management of antipsychotic-induced obesity - a systematic literature review
    Vasile, D.
    Vasiliu, O.
    Fainarea, A. F.
    Patrascu, M. C.
    Morariu, E. A.
    Androne, F. T.
    Vasiliu, D. G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S928 - S929
  • [7] Management of acromegaly in pregnancy: Case report and literature review
    Fernandez, Alberto
    Noval, Susana
    De La Calle, Maria
    Perez Alvarez, Marcelino
    Alvarez Escola, Cristina
    ENDOCRINOLOGIA Y NUTRICION, 2013, 60 (02): : 102 - 105
  • [8] Pharmacological management of cherubism: A systematic review
    Cailleaux, Pierre-Emmanuel
    Porporatti, Andre Luis
    Cohen-Solal, Martine
    Kadlub, Natacha
    Coudert, Amelie E.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [9] Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
    Neggers, Sebastian J. C. M. M.
    Pronin, Vyacheslav
    Balcere, Inga
    Lee, Moon-Kyu
    Rozhinskaya, Liudmila
    Bronstein, Marcello D.
    Gadelha, Monica R.
    Maisonobe, Pascal
    Sert, Caroline
    van der Lely, Aart Jan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 173 (03) : 313 - 323
  • [10] Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
    Feuilly, M.
    Jenni, E.
    Cella, D.
    NEUROENDOCRINOLOGY, 2020, 110 : 190 - 190